Synthesis, Characterization, X-ray Structure, DNA Cleavage, and Cytotoxic Activities of Palladium(II) Complexes of 4-Phenyl-3-thiosemicarbazide and Triphenylphosphane

Author(s)

Rocha, Fillipe Vieira ^[1] ; Barra, Carolina Valerio ^[1] ; Mauro, Antonio Eduardo ^[1] ; Carlos, Iracilda Z. ^[2] ; Nauton, Lionel ^[3] ; El Ghozzi, Malika ^[3] ; Gautier, Arnaud ^[3] ; Morel, Laurent ^[4] ; Godoy Netto, Adelino Vieira ^[1]

Affiliation

^[1] UNESP Univ Estadual Paulista, Dept Quim Geral & Inorgan, Inst Quim Araraquara, BR-14801970 Sao Paulo - Brazil

^[2] UNESP Univ Estadual Paulista, Fac Ciencias Farmaceut Araraquara, Dept Anal Clin, BR-14801902 Sao Paulo - Brazil

^[3] Univ Clermont Ferrand, Clermont Univ, ICCF, CNRS UMR 6296, F-63177 Aubiere - France

^[4] Univ Clermont Ferrand, Clermont Univ, GreD UMR CNRS 6247, INSERM U931, F-63177 Aubiere - France

• Document type: Journal article
• Source: European Journal of Inorganic Chemistry; v. 2013, n. 25, p. 4499-4505, SEP 2 2013.
• Web of Science Citations: 18

Abstract

Complexes of the type {[}PdX(PPh3)(1)]X {[}1 = 4-phenyl-3-thiosemicarbazide; X = Cl- (2), Br- (3), I- (4), and SCN- (5)] have been synthesized and characterized by elemental analyses and IR, UV/Vis, and H-1 and C-13 NMR spectroscopy. The molecular structure of complex 4 was determined by single-crystal X-ray diffraction. The binding of the complexes with a purine base (guanosine) was investigated by H-1 NMR spectroscopy and mass spectrometry, which showed the complexes to coordinate to guanosine through N7. A gel electrophoresis assay demonstrated the ability of 2-5 to cleave DNA plasmid. All the complexes were tested in vitro by means of the MTT assay for their cytotoxicity against two murine cell lines, LM3 (mammary adenocarcinoma) and LP07 (lung adenocarcinoma), and compared with cisplatin. Complexes 2-5 exhibited good cytotoxicity that surpasses that of cisplatin in the case of LM3. (AU)

• FAPESP's process: 12/15486-3 - Pd(II) compounds: synthesis, cytotoxicity, and DNA binding studies
• Grantee: Regina Celia Galvao Frem
• Support Opportunities: Regular Research Grants